The Academy of Pharmaceutical Physicians and Investigators (APPI) has joined the Clinical Trials Transformation Initiative (CTTI).
The CTTI was founded recently by the U.S. Food and Drug Administration (FDA) and Duke University as a public-private partnership of organizations that seeks to improve the quality and efficiency of clinical trials in the United States. As described here, CTTI was formed in the wake of growing frustration among patients, consumers, the academic community, and industry over the difficulty of conducting high-quality clinical trials in a timely manner that could produce information physicians need to define optimal treatments for their patients.
“As the leaders of the clinical research teams that test the safety and efficacy of potential new drugs and devices, physician investigators are in the prime position to spearhead efforts to make the trials process work better,” says Charles M. Alexander, MD, FACP, FACE, president-elect of APPI. “Our goal in joining CTTI is to support its collaborative efforts on behalf of everyone from the human subject volunteers in clinical trials to the researchers to the patients who will benefit in the future from FDA-approved products.”To read the full story in the July issue of the APPI Bulletin, click here.For more information about the APPI Bulletin, click here.